Monocytes and CART cell response in multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at how certain immune cells (monocytes) affect the success of CART cell therapy for multiple myeloma. It may help doctors improve treatment for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma.
- Your doctor has recommended CART cell therapy.
- You have health insurance or similar coverage.
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This study tests a new drug for people whose multiple myeloma has returned after a stem cell transplant. The goal is to see if it can control the cancer, and you must be healthy enough to participate.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.